Navigation Links
Researchers Design Promising Cancer Drug
Date:3/7/2008

It activates p53 tumor-suppressor function without causing DNA damage

FRIDAY, March 7 (HealthDay News) -- A drug that targets a protein interaction involved in many types of cancer has been created by University of Michigan researchers.

In cell cultures, the small-molecule inhibitor MI-219 was highly effective at preventing the tumor-suppressor function of the protein p53 from being blocked in the presence of a protein called MDM2.

In animals with human cancer, MI-219 completely inhibited tumor growth and appeared to cause no severe side effects.

"For more than 10 years, scientists have searched for ways to block p53 inhibition, but with little success. Our study clearly shows that this can be done," study author Shaomeng Wang, a professor of medicine at the U-M Medical School and co-director of the molecular therapeutics program at the U-M Comprehensive Cancer Center, said in a prepared statement.

The research was published online this week in the Proceedings of the National Academy of Sciences.

Clinical trials of the drug could begin by the end of 2008. If the drug proves safe and effective in humans, it could potentially be used to treat many kinds of cancer, according to the researchers.

In almost all types of human cancer, p53 is inactivated. About half the time, this is because the protein MDM2 binds to p53 and inhibits the tumor-suppressor function of p53. In other cases, p53 dysfunction is due to a missing or mutated gene.

"Many traditional cancer drugs also activate p53, but they do so by causing DNA damage. They kill not only tumor cells but also normal cells, thus having severe side effects. MI-219 is unique in that it is designed to activate p53 without causing DNA damage, specifically killing tumor cells," Wang said.

The University of Michigan has filed a patent application for MI-219 and its related molecules. The technology has been licensed by Ascenta Therapeutics Inc., which helped fund the study. Wang is a scientific founder of Ascenta, serves as its chief scientific adviser, and is the principal investigator on a research contract from Ascenta to U-M.

More information

The National Cancer Institute has more about cancer.



-- Robert Preidt



SOURCE: University of Michigan, news release, March 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Case Western Reserve University researchers identify colorectal cancer gene
2. On a roll: MIT researchers devise new cell-sorting system
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Researchers control growth rate of replacement blood vessels, tissues
5. New protein discovery helps researchers understand autoimmune diseases
6. UF researchers warn parents about dangers of childhood foot burns
7. UCLA researchers find blood stem cells originate and are nurtured in the placenta
8. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
9. Einstein researchers discover gene mutations linked to longer lifespans
10. U-M researchers ID promising new cancer drug
11. Researchers identify new genetic marker for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Design Promising Cancer Drug
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
Breaking Medicine Technology: